Attached files

file filename
S-1 - S-1 - Phio Pharmaceuticals Corp.d271779ds1.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

RXi Pharmaceuticals Corporation

Marlborough, Massachusetts

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 30, 2016 (except for the stock split discussed in Note 13, as to which date is April 18, 2016), relating to the financial statements of RXi Pharmaceuticals Corporation, which is contained in that Prospectus.

We also consent to the reference to us under the caption “Experts” in the Prospectus.

 

/s/ BDO USA, LLP
Boston, MA
October 21, 2016